Tags

Type your tag names separated by a space and hit enter

Interpreting clinical trials of diabetic dyslipidaemia: new insights.
Diabetes Obes Metab 2009; 11(3):261-70DO

Abstract

Current treatment guidelines highlight the importance of aggressive lipid-modifying therapy in reducing cardiovascular risk in patients with type 2 diabetes. Statins are established as the cornerstone of dyslipidaemia management in diabetic patients, based on their efficacy in lowering levels of low-density lipoprotein cholesterol (LDL-C). However, statins fail to address the high residual cardiovascular risk in treated patients, some of which may be attributable to low HDL cholesterol (HDL-C) and elevated triglycerides and to a preponderance of small, dense LDL particles, indicating the need for further intervention. Fibrates are effective against all components of atherogenic dyslipidaemia associated with type 2 diabetes. Clinical studies, most notably the Fenofibrate Intervention and Event Lowering in Diabetes, indicate that fibrates, most likely in combination with a statin, have a secondary role in reducing cardiovascular risk in patients with type 2 diabetes, particularly in those without prior cardiovascular disease or patients with low HDL-C. Results are awaited from the ongoing Action to Control Cardiovascular Risk in Diabetes trial to fully evaluate the outcome benefits of this combination strategy.

Authors+Show Affiliations

Department of Chemical Pathology, St Thomas' Hospital, London, UK. anthony.wierzbicki@kcl.ac.uk

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17645560

Citation

Wierzbicki, A S.. "Interpreting Clinical Trials of Diabetic Dyslipidaemia: New Insights." Diabetes, Obesity & Metabolism, vol. 11, no. 3, 2009, pp. 261-70.
Wierzbicki AS. Interpreting clinical trials of diabetic dyslipidaemia: new insights. Diabetes Obes Metab. 2009;11(3):261-70.
Wierzbicki, A. S. (2009). Interpreting clinical trials of diabetic dyslipidaemia: new insights. Diabetes, Obesity & Metabolism, 11(3), pp. 261-70.
Wierzbicki AS. Interpreting Clinical Trials of Diabetic Dyslipidaemia: New Insights. Diabetes Obes Metab. 2009;11(3):261-70. PubMed PMID: 17645560.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interpreting clinical trials of diabetic dyslipidaemia: new insights. A1 - Wierzbicki,A S, Y1 - 2007/07/21/ PY - 2007/7/25/pubmed PY - 2009/11/3/medline PY - 2007/7/25/entrez SP - 261 EP - 70 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 11 IS - 3 N2 - Current treatment guidelines highlight the importance of aggressive lipid-modifying therapy in reducing cardiovascular risk in patients with type 2 diabetes. Statins are established as the cornerstone of dyslipidaemia management in diabetic patients, based on their efficacy in lowering levels of low-density lipoprotein cholesterol (LDL-C). However, statins fail to address the high residual cardiovascular risk in treated patients, some of which may be attributable to low HDL cholesterol (HDL-C) and elevated triglycerides and to a preponderance of small, dense LDL particles, indicating the need for further intervention. Fibrates are effective against all components of atherogenic dyslipidaemia associated with type 2 diabetes. Clinical studies, most notably the Fenofibrate Intervention and Event Lowering in Diabetes, indicate that fibrates, most likely in combination with a statin, have a secondary role in reducing cardiovascular risk in patients with type 2 diabetes, particularly in those without prior cardiovascular disease or patients with low HDL-C. Results are awaited from the ongoing Action to Control Cardiovascular Risk in Diabetes trial to fully evaluate the outcome benefits of this combination strategy. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/17645560/Interpreting_clinical_trials_of_diabetic_dyslipidaemia:_new_insights_ L2 - https://doi.org/10.1111/j.1463-1326.2007.00751.x DB - PRIME DP - Unbound Medicine ER -